cyclophosphamide + doxorubicin + methotrexate + cytarabine

This drug is a **multi-agent chemotherapy combination** composed of cyclophosphamide, doxorubicin, methotrexate, and cytarabine. Each component is a cytotoxic small molecule agent, commonly used in oncology: cyclophosphamide is an alkylating agent that cross-links DNA; doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II; methotrexate is an anti-folate that inhibits dihydrofolate reductase, disrupting DNA synthesis; cytarabine is a nucleoside analog that inhibits DNA polymerase. While several two- and three-drug combinations from these components are standard (e.g., CHOP, AC, CODOX-M, etc.), there is no established, named, or widely recognized four-drug regimen using only these four agents together as a canonical protocol in adult or pediatric oncology based on present evidence.